Posted on 6/21/19
Teva: Common Law Vs. Civil Law Misperceptions Can Be Devastating
SummaryTeva's stock has reached multi-year lows and can't find steady support after the decision has been made to settle the first opioid case.There is a distant . . .
Posted on 11/26/18
United Therapeutics: Value Company With Growth Prospects
Summary United Therapeutics, a $5 bn market cap company, is traded at one of the lowest comparable multiples in biotech space. Investors are concerned about uncertainty . . .
Posted on 11/26/18
United Therapeutics: Value Company With Growth Prospects
SummaryUnited Therapeutics, a $5 bn market cap company, is traded at one of the lowest comparable multiples in biotech space.Investors are concerned about uncertainty associated with . . .
Posted on 11/14/18
Biogen: Spinning Around Spinraza
SummaryBiogen is a solid biotech company with established revenue streams and strong financials.The short-term growth of the company is heavily dependent on Spinraza's ex-US sales.We are . . .
Posted on 10/30/18
Vertex: Great Company But Too Pricey
SummaryVertex is a $42 bn market cap biotech company that showed unprecedented success over the last several years in the treatment of cystic fibrosis.We believe that . . .
Posted on 2/20/18
Is Celgene A Growth Or A Value Stock?
Celgene's Long-Lasting UnderperformanceIf an average Joe invested $100 in Celgene's (NASDAQ:CELG) stock in 2015, he would have lost $17 now. At the same time, if he . . .
Pittsburgh
